Ascendis Pharma FY 2025 Results: More Than A Takeover Story

Ascendis Pharma has transitioned into a revenue-scaled commercial biotech, driven by Yorvipath's rapid adoption and strong FY25 results. ASND's 2025 product revenue surged to €684 million, with Yorvipath accounting for nearly 70% and operating profit turning positive in 4Q25. TransCon CNP's upcoming FDA decision is a major catalyst, but ASND now offers multiple commercial drivers, reducing binary risk.

Seeking Alpha • Feb 12, 2026

Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript

Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 12, 2026

Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results

COPENHAGEN, Denmark, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.

GlobeNewsWire • Feb 11, 2026

Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026

COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday, February 11, 2026, after the close of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on February 11, 2026, at 4:30 p.m.

GlobeNewsWire • Feb 4, 2026

Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains?

Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Investment Research • Jan 14, 2026

Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 12, 2026

Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference

COPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2026 key corporate milestones. Ascendis President and CEO Jan Mikkelsen will present this update on Monday, January 12, during the 44th Annual J.P.

GlobeNewsWire • Jan 9, 2026

Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript

Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript

Seeking Alpha • Jan 9, 2026

Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)

– Once-weekly TransCon ® CNP and TransCon ® hGH combination therapy showed durable growth without compromising safety or tolerability at 52 weeks – Annualized growth velocity (AGV) exceeded the 97th-percentile of average stature children – ACH height Z-score improvements indicated a tripling of efficacy compared to TransCon CNP monotherapy – Combination therapy demonstrated benefits beyond linear growth with improvements in body proportionality and arm span, aligning with the increase in linear growth – All children completed 52 weeks of treatment and remain on therapy in COACH as of today – Combination therapy was generally well tolerated, with generally mild treatment-emergent adverse events (TEAEs), consistent with TransCon CNP and TransCon hGH monotherapies – Ascendis to host conference call today at 4:30pm ET  COPENHAGEN, Denmark, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced topline results from Week 52 of COACH, the first Phase 2 clinical trial to evaluate combination therapy with once-weekly TransCon CNP (navepegritide) and once-weekly TransCon hGH (lonapegsomatropin) in children with achondroplasia. At Week 52, combination therapy showed durable growth without compromising safety or tolerability.

GlobeNewsWire • Jan 8, 2026

Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference

COPENHAGEN, Denmark, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the 44th Annual J.P. Morgan Healthcare Conference and provide a business update on Monday, January 12, 2026, at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time in San Francisco, California.

GlobeNewsWire • Jan 5, 2026